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Abstract
Background: Despite optimal therapy, many children with Crohn’s disease (CD) experience growth retardation.
The objectives of the study are to assess the feasibility of a randomised control trial (RCT) of injectable forms of
growth-promoting therapy and to survey the attitudes of children with CD and their parents to it.
Methods: A feasibility study was carried out to determine study arms, sample size and numbers of eligible patients.
A face-to-face questionnaire surveyed willingness to consent to future participation in the RCT. Eligibility to the
survey was any child under 18 (with their parent/guardian) with CD whose height standard deviation score (HtSDS)
was ≤+1. Of 118 questionnaires, 94 (80%) were returned (48 by children and 46 by parents).
Results: The median age of the patients in the survey was 14.3 years (range 7.0 to 17.7), and 35 (73%) were male.
Their median HtSDS was −1.2 (−3.01, 0.23), and it was lower than the median mid-parental HtSDS of −0.6 (−3.1, 1.4).
We analysed the willingness of the children whose HtSDS <−1 to take part in the proposed RCT, being those most
likely to require treatment. Overall, 18 (47%) children and 17 (46%) parents were willing. This increased to 61% of
children who were slightly concerned about their height and 100% (4/4) of those very concerned. A common
reason for not taking part in the RCT was fear of injections (44%); 111 children are required for randomisation into
three study arms from nine centres.
Conclusions: Almost half of children and parents surveyed would take part in an RCT of growth-promoting
therapy. Allaying fears about injections may result in higher recruitment rates.
Keywords: Growth retardation, Inflammatory bowel disease, Crohn’s disease, Puberty, Growth hormone, Insulin-like
growth factor-1
Background
Around one quarter of cases of Crohn’s disease (CD) are
diagnosed in children under 18, with the incidence in
childhood increasing [1]. Growth failure is a common
manifestation and may be the first presentation of disease
[2]. Despite advances in CD treatments [3], around 20% of
affected children may continue to grow slowly [4] and
remain short on reaching their final adult height [5, 6].
The cause of growth failure is multi-factorial and in-
cludes poor nutrition, inflammation and corticosteroid
treatment. The mechanisms involve a disturbance of
growth hormone insulin-like growth factor-1 axis (GH-
IGF-1) at peripheral and central levels [7]. Although the
exact mechanisms of disturbance of the GH-IGF-1 axis
in CD are still not fully elucidated, the abnormalities
may range from functional GH deficiency to GH resistance
with low circulating IGF-1 [7–10]. Current treatment is to
improve growth using steroid-sparing anti-inflammatory
medication [11].
Preliminary evidence from the use of recombinant
growth hormone (rhGH) therapy in CD children in our
centres and from centres in the USA indicates its potential
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efficacy despite the expected insensitivity to GH [12–14].
However, there are no randomised control trials (RCTs)
that investigate recombinant human insulin-like growth
factor-1 (rhIGF-1) alone or in combination with rhGH on
growth of children with CD. As GH acts through IGF-1
and because children with Crohn’s disease have low circu-
lating IGF-1, rhIGF-1 is worthy of consideration, being effi-
cacious in stimulating growth in children with conditions
associated with GH insensitivity (reviewed in [10]).
It is, therefore, possible that the use of rhGH and/or
rhIGF-1 might enhance the growth of children with
Crohn’s disease with growth failure, over and above that
achieved with optimal anti-inflammatory therapy. The
rationale for conducting a future study was to determine
if we could develop a treatment strategy to combat
growth failure in children with Crohn’s disease. There
are, however, concerns with regard to the acceptability
of conducting such a trial to both patients with CD and
their families. It is important to establish whether it is
feasible to conduct a trial of this nature. We, therefore,
undertook a feasibility study to:
 Survey the attitudes of parents and patients towards
the proposed RCT
 Establish an experimental design (including the
number of arms with different treatments)
 Estimate the number of patients with CD who
would potentially be available from UK centres
 Identify suitable sites and collaborators
 Establish the required sample size
Methods
We applied to the appropriate Medicines for Children
Clinical Studies Group (CSG) of the National Institute
for Health Research (NIHR) whose remit is to help the
NIHR define research priorities and to develop a port-
folio of clinical studies to be run across the NIHR
Medicines for Children network. It is the purpose of
the CSG to determine if a question is scientifically
valid and clinically important. It includes parent and
patient involvement. We obtained a satisfactory out-
come to examine the feasibility of a trial of injectable
growth-promoting drugs with a view to establishing an
RCT, before applying for funds from Crohn’s in Childhood
Research Association (CICRA). CICRA undertook peer
review using standards approved by the Association
Medical Research Charities (AMRC).
The Medicines for Children’s Clinical Trials Unit
(MC CTU) administered the feasibility study which
included 10 monthly trial management group (TMG)
meetings either by teleconference or face to face.
Minutes of these meetings were recorded and made
available to all members.
Patient survey
Two questionnaire surveys were developed for two
groups: potential participants for the trial (Additional
file 1) and their parents (Additional file 2). These ques-
tionnaires were developed by the TMG, and their format
was based on a successful earlier questionnaire survey by
the MC-CTU [15]. As the questionnaire was a survey on
participants’ willingness to consent to a future trial, it did
not require research ethics committee approval, as long as
the answers to the questionnaires remained anonymous,
as determined by the Barts Health NHS Trust R&D office.
Anonymity was important to avoid the possibility of par-
ents and children giving different answers because they
thought that their healthcare provider could see and iden-
tify them. Information sheets were written for the clin-
ical teams, which included a description of the four
possible arms of the RCT: (1) treatment to combat in-
flammation, (2) added injections of recombinant human
growth hormone (rhGH), (3) added injections of recom-
binant human insulin-like growth factor (rhIGF), and (4)
added rhGH and rhIGF-1.
Content validity was assessed through questionnaires
piloted on five patients and their parents. They were
amended based on feedback and then sent to a wider
group. The questions (Additional files 1 and 2) included
demographic data: age, height on the day of attending
clinic and parental height. Specific questions included
their degree of concern regarding their height, attitudes
to injections to improve growth, willingness to join an
RCT and any previous growth-promoting drugs. All
questionnaires were anonymous, and no patient identifi-
able data were collected. Parents and patients in the same
family were given a single study number to enable com-
parison of responses.
Participants
Questionnaires were distributed in two paediatric in-
flammatory bowel disease (IBD) outpatient clinics (Barts
Health (London) and Royal Hospital for Sick Children
(Glasgow)) to consecutive participants between 1 March
and 31 July 2014. One further centre that was invited
did not administer questionnaires because of limitations
in research capacity. The target recruitment at each of
the centres was at least 30 patient questionnaires and 30
parent questionnaires. The child questionnaire was
completed by a patient with CD who fulfilled the eli-
gibility criteria (height standard deviation score
(HtSDS) was ≤+1), and only the 38 children with
HtSDS ≤−1 were included in the attitude analysis
because only children whose HtSDS was <−1 were to be
included in the RCT (see below). One of the child’s
parents completed the parental questionnaire. In two chil-
dren who participated, the parents did not answer a ques-
tionnaire. We, therefore, analysed questionnaires from 38
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children and 36 parents for the attitude analysis. A health-
care worker was available to explain the meaning of any
questions that a child or parent did not understand but
was not involved in recording the answers.
Completed questionnaires were sent back to the MC
CTU for initial result collation. For the study partici-
pants, height was measured with a Harpenden stadi-
ometer and converted into standard deviation scores
(SDS) for chronological age using 1990 UK standards
[16]. The HtSDS is the number of standard deviations
that a particular child deviates above (+) or below (−)
the mean for that child’s age. Mid-parental height
(MPH) and MPH SDS were calculated from reported
parenteral heights.
Survey of paediatric gastroenterologists
A letter was sent to 18 paediatric IBD centres in the UK
and to 6 general paediatric centres with an interest in
gastroenterology. These explained the feasibility study in
terms of a possible future RCT. It also asked for the num-
bers of children with Crohn’s disease managed under their
care. A 2-week timeline was given to receive replies.
Analysis
Data were analysed using Minitab software version 17
and SAS (version 9.2). Non-parametric data are pre-
sented with medians and ranges. For categorical vari-
ables, percentages were calculated. Missing responses
were not included in the descriptive analyses.
Results
The eligibility was determined in two centres (Barts
Health and Glasgow), by studying children with CD who
had severe growth failure (HtSDS <−1 combined with a
reduction in HtSDS or 0.5 more over 1 year).
Survey results
Willingness to consent was surveyed using question-
naires in children with short stature (HtSDS <+1). This
number included a wider range than our proposed treat-
ment group. This would allow us to determine if height
might affect a participant’s willingness to undertake the
study. However, in order to more closely align our re-
sults with a proposed RCT, we analysed the willingness
of only those children with an HtSDS <−1. Nevertheless,
it was not possible to make a reduction of 0.5 HtSDS a
criterion for inclusion into the survey because that
would have lost anonymity: although a static HtSDS can
be calculated from an anonymous survey (parents know
the age of their child, and the height measured in outpa-
tients), calculating a change in HtSDS over a year requires
access to medical records (which are not anonymous) to
determine earlier heights and their dates of measurement.
The overall response rate was 78% (48 (80%) out of 60
questionnaires were completed by children and 46 (77%)
out of 60 were completed by parents). Participants’
demographics, anthropometric and clinical information
are presented in Table 1. Of the 48 children, 4 (9%) had
been specifically treated with a growth-promoting
therapy before (n = 2 received rhGH and n = 2 received
testosterone). The responses from children and parents
to the survey’s questions are summarised in Table 2. In
31 cases, there was agreement with regard to how
concerned a child and their parent were with the
child’s height.
The results of cross-tabulation of question 1 (How
concerned are you about your/your child’s height?) and
question 6 (If the RCT we had in mind was happening
now, would you be willing for your child to join?) are
shown in Tables 3 and 4 for participants with HtSDS <−1,
for children and their parents, respectively; 11/38 (47%) of
children were willing to participate in a future RCT.
Although 4/17 (23%) patients were not concerned
about their height, they were willing to participate
[median HtSDS (range) for patients who were will-
ing, −1.3 (−2.2 to −1.0), and not willing, −1.1 (−1.5
to −1.0), to participate in the RCT]. Furthermore,
11/18 (61%) children who were slightly concerned
about their height responded that they would be
happy to participate in the RCT [median (range)
HtSDS was −1.6 (−3.0 to −1.0) compared to 7/18
(39%) who were slightly concerned and not willing
to participate, −1.3 (−1.95 to −1.0)]. All very concerned
children were willing to take part if the RCT went forward
[median (range) HtSDS −2.1 (−2.5 to −1.2)]. In summary,
therefore, at least 60% of children who showed concern
about their height would be willing to take part in an RCT
of injectable therapy.
Although 8/19 (42%) parents were not concerned
about their children’s growth, they were willing to have
their children participate in the RCT. The median
(range) HtSDS of these children was −1.4 (−3.0 to −1.0),
compared to −1.4 (−2.0 to −1.0) for children of the 11/
19 (58%) parents who were not concerned and not
willing to participate in the RCT. In contrast, 7/11 (64%)
of parents who were slightly concerned were willing for
Table 1 Demographic, anthropometry and clinical characteristics
Total n = 48 (80%)
Age/year (range) 14.3 (7.0, 17.7)
Sex (M), n (%) 35 (73)
HtSDS (range) −1.2 (−3.01, 0.89)
MPHSDS (range) −0.59 (−3.14, 1.4)
Treated for growth problem, n (%) 4 (8)
Family history of CD, n (%) 8 (17)
MPHSDS mid-parental height SDS, HtSDS height SDS score, CD Crohn’s disease
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their children to join the RCT. The median (range)
HtSDS [−1.4 (−2.3 to −1.0) vs. −1.2 (−1.6 to −1.0), re-
spectively] of these two groups were similar. In addition,
4/5 (80%) of very concerned parents were willing for
their children to participate in the RCT [median (range)
HtSDS −1.8 (−2.5 to −1.1)].
The median (range) HtSDS [−1.5 (−3.01 to −1.0)]
in the concerned children was lower than that in the
non-concerned group [median (range) HtSDS −1.1
(−2.2 to −1.0)] (Fig. 1a). Their gender distribution,
however, was found to be similar (15 M/6 F vs. 12 M/5 F).
Also, the MPHSDS [−0.7 (−3.1 to 0.54) vs. −0.7 (−2.2 to
0.63)] among concerned and non-concerned children
were similar. The 18/38 (47%) children who were willing
to participate in the RCT were shorter [median (range)
with a HtSDS −1.6 (−3.0 to −1.0)] than the 20 (53%)
who were not willing to participate in RCT [median
(range) HtSDS −1.1 (−1.9 to −1.0)] (Fig. 1b; but, these
two groups were similar with respect to their gender
(12 M/6 F vs. 15 M/5 F)).
The major reasons for not wishing to participate in
the RCT were identified by 18 children: 8 (44%) of them
stated the fear of injections, 8 (44%) stated that they
were not concerned about their height, 1 (6%) partici-
pant was already on many drugs and 1 (6%) difficulty in
taking time off from college.
Study design including number of arms
During the period of the feasibility study, the avail-
ability of rhIGF-1 for research was discontinued, due
to manufacturing problems and the need to conserve
stocks for children in clinical need. This necessitated
a complete change in study design, as two of the
arms, originally envisaged, included rhIGF-1. We
therefore chose a three-arm design with two rhGH
doses. The doses were chosen for the following rea-
sons: one dose was that used in our preliminary study
[14] and the second dose was that used clinically to
Table 2 The responses from children and parents to survey’s
questions
Total
Question Response Parents
(n = 46)
Child
(n = 48)
1 How concerned are
you about your child’s
height?
Not concerned 29 (63%) 26 (54%)
Slightly
concerned
11 (24%) 19 (40%)
Very concerned 5 (11%) 3 (6%)
Missing 1 (2%)
2 Do you think it is worth
doctors trying to find a
better treatment for
growth in Crohn’s disease?
Yes 40 (87%) 42 (88%)
No 4 (9%) 5 (10%)
Missing 2 (4%) 1 (2%)
3 Do you think that the
opportunity of gaining
extra height is worth
a year of daily injections?
Yes 25 (54%) 20 (41%)
No 19 (41%) 28 (58%)
Missing 2 (4%) 0
4 We have explained that
in an RCT you are not
able to choose which
treatment your child
would receive. Would
you be comfortable
with this?
Yes 20 (44%) 24 (50%)
No 25 (54%) 23 (47%)
Missing 1 (2%) 1 (2%)
5 Would you and your
child be willing to
attend to have your
child’s growth and
other things checked
(e.g. quality of life)
if it sometimes means
an extra visit (1 or 2
extra in a year)?
Yes 34 (74%) 36 (75%)
No 10 (22%) 12 (25%)
Missing 2 (4%) 0
6 If the RCT we had in
mind was happening
now, would you be
willing for your
child to join?
Yes 22 (48%) 21 (44%)
No 23 (50%) 27 (56%)
Missing 1 (2%) 0
Table 3 Children’s willingness to participate. Cross-tabulation of
questions was examined to understand if a child’s attitude to their
height influenced their willingness to have injectable treatment:
question 1 (How concerned are you about your height?) was
compared to question 6 (If the RCT we had in mind was happen-
ing now, would you be willing to join?) for children (n = 38)
Question 6
If the RCT we had in mind
was happening now, would
you be willing to join?
Total
Question 1
How concerned
are you about
your height?
No Yes
Not concerned n (%) 13 (76%) 4 (23%)
Slightly concerned n (%) 7 (39%) 11 (61%)
Very concerned n (%) 0 (0%) 3 (100%)
Table 4 Parents’ willingness to participate. Cross-tabulation of
question 1 (How concerned are you about your child’s height?) and
question 6 (If the RCT we had in mind was happening now, would
you be willing for your child to join?) for parents (n= 36) (missing
data for relevant questions from returned questionnaires = 1)
Question 6
If the RCT we had in mind
was happening now,
would you be willing for
your child to join?
Total
Question 1
How concerned
are you about
your child’s height?
No Yes
Not concerned n (%) 11 (58%) 8 (42%)
Slightly concerned n (%) 4 (36%) 7 (64%)
Very concerned n (%) 1 (20%) 4 (80%)
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stimulate growth in other chronic diseases of child-
hood such as renal failure and cystic fibrosis. We had
thought that the problem of supply had been resolved
during the preparation of this manuscript, but after
further discussions with the company after our ori-
ginal submission, we were informed that stocks were
not large enough to include children with CD.
Sample size
The sample size for the proposed trial was based on
a desirable increase of +0.5 HtSDS. While the de-
sired amount of growth stimulated by medical inter-
vention has been the subject of debate, an increase
of 0.5 HtSDS is that recommended by a joint collab-
oration of paediatric endocrinologists across Europe
and North America [17]. It was also based on effi-
cacy of rhGH in a preliminary study of 22 children
randomly allocated to receive rhGH [14]. The power
calculation was based on this prior data [14] that re-
ports a range of HtSDS of [−0.9; 2.0]. A simple, ap-
proximate, way to estimate the standard deviation
from the range is by dividing the range by four
which results in an estimated standard deviation of
0.725. This informs a power calculation as described
by Jaki and Magirr [18] with a structure that allows
for one final analysis. To detect a difference between
any one dose (rhGH 0.067 or 0.035 mg/kg/day) and
optimal anti-inflammatory therapy and optimal anti-
inflammatory therapy alone of 0.5 HtSDS (approx.
3.5 cm) with alpha = 5% (one-sided family-wise error
rate) and 80% power (1-beta = 0.8) requires recruit-
ment of 99 participants with complete primary out-
come, with 33 in each arm.
Numbers of potential participants from a population of
children with Crohn’s disease
To estimate what proportion of children with CD would
be eligible for the proposed trial, we used estimates from
the eligible patients at two sites (Glasgow and London)
and also the results from the survey of parents and chil-
dren. The databases at the two centres indicated that for
every 100 children with CD, seven would fit the inclu-
sion criteria of the study. Based on the survey data of
children who were concerned about their height, 60% of
these would then agree to consent and take part in the
trial; thus, 4.2% of patients diagnosed with CD will be
eligible. There were no dropouts in the preliminary
study [14] undertaken in two of our centres. However,
the MC CTU advised that it would be prudent to as-
sume that 10% will not provide primary outcome data.
We, therefore, would expect approximately 3–4 of every
100 patients with CD to be eligible, consent and provide
complete primary outcome data (3.78%) (Fig. 2).
We then also estimated the numbers of patients who
would present with growth failure over the first 2 years
of a 3-year study. Based on Barts Health NHS Trust
electronic data, for every 100 children currently attend-
ing the Inflammatory Bowel Disease clinic with Crohn’s
disease, 25 new cases of CD are diagnosed each year.
Assuming this ratio of new cases to prevalent cases is uni-
form, then for every 100 CD cases currently with growth
failure, an extra 50 cases would present in the next 2 years
(because the proportion of children with growth failure
does not change with time, we can calculate the numbers
of children who will present with growth failure from
cases diagnosed in earlier years by determining the num-
ber of new cases CD in a current year).
(a) (b)
Fig. 1 Differences in HtSDS between children who were concerned and those who were not concerned about their height (a) and difference in
HtSDS between children who are willing to participate in randomised controlled trial and those who are not willing (b). HtSDS height SDS
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Sites and collaborators
We sent a letter to each paediatric gastroenterologist
leading a paediatric IBD centre and to each paediatrician
with an interest in gastroenterology; 14 of 18 paediatric
IBD centres responded to the letter requesting the num-
ber of children with CD under their care (response rate
78%, excluding those conducting the feasibility study
whose numbers we knew). No general paediatrician with
Fig. 2 Flow diagram of the proposed future multi-centre study on the efficacy and mechanism of recombinant human growth hormone (rhGH)
in children with Crohn’s disease-induced growth failure
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an interest in gastroenterology (and therefore not work-
ing in a paediatric IBD centre) responded. The median
size of each major UK paediatric IBD centre was ap-
proximately 200 [range 85–320]. If the study were to re-
cruit over 2 years, there would be approximately 300
potentially eligible children, to include both 200 current
and 100 patients presenting with growth failure in the
next 2 years. To enrol 99 participants that are eligible,
consent and provide complete primary outcome data in
the trial, 2643 cases need to be screened (Fig. 2). Thus,
approximately nine sites would be required to take part
in the study to recruit the necessary participants.
Discussion
This is the first feasibility study of an RCT in growth-
promoting therapy in children with CD. It is also the
first quantitative study to survey the attitude of children
with CD and their parents towards endocrine therapy
for growth promotion in an RCT. The possible treat-
ments, in addition to optimal anti-inflammatory therapy
(standard treatment), included daily injections of rhGH,
rhIGF-1 or rhGH and rhIGF-1 in the survey. Many chil-
dren with CD and their parents would take part in an
RCT of growth-promoting therapy despite only a minor-
ity being very concerned about their height. However,
answers may differ when confronted with consent to an
ongoing trial, rather than a hypothetical one. Concerns
about height were more likely in those who were shorter,
and shorter children were more likely to consider this
additional therapy to promote their growth.
The results of our survey can be compared with a pre-
liminary RCT on rhGH in children with IBD [14]. In
that study, all patients approached agreed to enter the
study. The reasons why this proportion is so much
greater include the possibility that 6 months of injec-
tions are less daunting than a year and also that the in-
clusion criteria in that study included a fall in height
SDS (or decreased height velocity, which is the same
concept differently expressed) and this made participants
more keen to engage.
Reports show that boys are more vulnerable to the
psychological burden of being short than are girls [19];
however, we did not find any gender difference in their
concerns over height. The majority of our participants
were boys (73%), and this may have influenced our re-
sults. Major reasons for not taking part in the proposed
RCT reported by children in the survey were fear of in-
jections and not being concerned about their height. Al-
leviating fear of injections in eligible participants may
result in higher recruitment rates.
The degree of concern about height correlated with an
interest in taking part in the proposed RCT, with 100%
of very concerned patients willing to participate. Simi-
larly, in a survey examining patients’ perceptions of
faecal microbiota transplantation for ulcerative colitis
(UC), all patients with severe UC were willing to take
part [20]; thus, the patients most affected by the condi-
tion it seems are the most likely to agree to any pro-
posed study.
Although currently, there is a lack of conclusive
data on rhGH in children with IBD, the initial results
suggest that rhGH may have a positive effect on
growth in the short term [12–14, 21, 22]. The avail-
able evidence has shown the growth-promoting effect
of rhGH on children with mild disease activity and
growth retardation. Thus, the effect rhGH on CD
children with intractable inflammation and growth re-
tardation remains unanswered. There is a need to
perform larger, more conclusive studies of rhGH ther-
apy which explore this issue.
Given that substantial cohort remains short despite
the use of optimal therapy and considering that the ab-
normality may occur at multiple levels of the GH/IGF-1
axis, the possible use of other forms of growth-
promoting agents such as rhIGF-1, either alone or in
combination with rhGH for promoting growth, also war-
rants further investigation. The studies of effects of
rhIGF-1 on growth on CD have not been described yet,
partly because of the theoretical risk of colon cancer in
patients with high levels of circulating IGF-1. However,
by using mathematical modelling to determine the dose
of rhIGF-1 that could be prescribed to maintain serum
IGF-1 levels within the physiological range, this study
may inform the design of future clinical trials [23]. How-
ever, during the course of the feasibility study, examin-
ation of rhIGF-1 as a possible therapeutic agent had to
be discontinued due to lack of supply.
One of the limitations of the survey was that the cri-
teria for inclusion into the study did not exactly match
the inclusion criteria for the proposed trial. As described
above, this was because a fall in HtSDS cannot be deter-
mined anonymously. An assumption was made that
those whose HtSDS had fallen by 0.5SDS would be con-
cerned about their height. This assumption could be cri-
ticised; nevertheless, a fall of 0.5SDS in an adult male is
equivalent to 4 cm, which is a change that is unlikely to
go unnoticed if it happened over a year. The fact that all
children in the preliminary study [14] agreed to partici-
pate leads us to conclude that 60% is not overoptimistic.
A second limitation was that exploring the reasons for
participants’ concern at being short was beyond the
scope of a questionnaire on willingness to consent.
Mason et al. [24] published the first study which showed
that short stature is associated with adverse quality of
life measured by IMPACT-III in the subdomain of body
image. It would, therefore, be beneficial to assess the im-
pact on quality of life in any future trial involving the
use of growth-promoting therapies.
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Conclusions
In summary, while we acknowledge that, while feasible,
the low proportion of children affected by growth failure
will make recruitment a challenge, this study indicated
that it was feasible to consider the initiation of a rando-
mised controlled trial of an injectable form of growth-
promoting therapy in children with CD. The majority of
those surveyed were interested despite only a minority
being very concerned about their height. By alleviating
fears about injections, it is likely that a future trial would
achieve the higher recruitment rates observed in the pre-
liminary study undertaken in two of our centres [14].
Additional files
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